Work

The Impact of Ketamine-Augmented Psychotherapy on Neurocognitive Factors in Unipolar Depressive Disorders: A Scoping Review

Year: 2026
Type: study-registration
Abstract: 1. Background and rationale Unipolar depressive disorders are associated with substantial symptom burden and functional impairment. Global burden-of-disease analyses document the considerable population-level impact of depressive disorders (Rong et al., 2025). In Germany, nationwide outpatient claims data indicate an increase in recorded depression diagnoses over time; such administrative trends should not be equated with changes in the underlying population prevalence (Steffen et al., 2020). The diagnostic experience and social framing of depression have also been examined, underscoring the complexity of how depressive suffering is understood and classified (Petersen & Madsen, 2017). Beyond affective symptoms, unipolar depression is associated with neurocognitive difficulties affecting attention, processing speed, learning, memory, inhibitory control, cognitive flexibility, and other executive functions. These difficulties are clinically relevant because cognitive deficits can be linked to impaired everyday functioning (McIntyre et al., 2013). Cognitive and psychosocial limitations may persist even after symptomatic response to conventional antidepressant treatment (Papalexi et al., 2022). Accordingly, neurocognitive symptoms constitute an important treatment target, as reflected in research reviewing therapeutic approaches to cognitive dysfunction in unipolar depression (Salagre et al., 2017). Ketamine and esketamine have been investigated as rapidly acting antidepressant interventions, particularly in major depressive disorder and treatment-resistant depression (TRD). The selected publication window begins in 2000, the year of an early placebo-controlled clinical study reporting antidepressant effects of ketamine in depressed patients (Berman et al., 2000). This starting date is a pragmatic methodological boundary, not a claim that ketamine or cognition research began in that year. This review focuses specifically on ketamine-augmented psychotherapy (KAP), defined as a protocol-specified combination of ketamine or esketamine administration with a structured psychotherapeutic intervention. Routine monitoring or non-specific supportive contact alone does not establish KAP. Because psychotherapy may be incompletely indexed in bibliographic records, the primary search will not require psychotherapy terms; eligibility screening will establish whether structured psychotherapy was delivered. The evidence may vary across ketamine protocols, psychotherapeutic approaches, cognitive instruments, assessment times, populations, and comparators. A scoping review is therefore appropriate to characterize the breadth of research and identify gaps rather than produce a single pooled efficacy estimate. Reporting will be guided by PRISMA-ScR and the JBI approach to scoping reviews. 2. Objectives and review question Primary objective: systematically map published evidence on objective and subjective neurocognitive changes in adults with unipolar depressive disorders receiving protocol-defined ketamine-augmented psychotherapy, and characterize the studies, populations, interventions, measurements, and comparison conditions represented. Review question: How do objectively and subjectively assessed neurocognitive factors change among adults with unipolar depressive disorders undergoing ketamine-augmented psychotherapy, and what study, population, intervention, and comparator characteristics are represented in the existing literature? Secondary mapping objectives include identifying studied cognitive domains, measures and assessment time points; describing ketamine/esketamine and psychotherapy protocols; distinguishing TRD populations; and locating evidence clusters and gaps. A comparator is not required for inclusion. 3. Eligibility criteria: Population–Concept–Context (PCC) Eligibility will be assessed against the Population–Concept–Context framework and prespecified study-design criteria rather than inferred from search filters. Scientific publications will be considered eligible if an abstract is available in either English or German, regardless of the language of the full-text publication. No language restrictions will be applied to the full texts of potentially eligible studies. Any limitations related to translation or full-text accessibility will be transparently documented. Reports without eligible primary empirical findings may inform contextual interpretation and citation tracking but will not be counted as included outcome studies. Table: Dimension --> Prespecified eligibility Population --> Adults aged ≥18 years with DSM-5, ICD-10, or ICD-11 diagnosed unipolar depressive disorder, including major depressive disorder and persistent depressive disorder. TRD is eligible and charted separately. Exclude bipolar depression, primary psychotic disorders, and substance-induced depressive disorders. Concept --> A protocol-defined combination of ketamine or esketamine and structured psychotherapy. At least one validated objective neuropsychological or subjective cognitive outcome is required. Pharmacological treatment alone and merely supportive clinical contact are insufficient. Context --> Outpatient, day-clinic, and inpatient settings in any country or healthcare system. Study designs --> Randomized controlled trials, quasi-experimental studies, prospective/retrospective cohorts, case-control studies, and case series with n ≥5. Comparator not mandatory. Publication period --> 1 January 2000 through the date of the final search update. Preparatory searches currently documented through 4 September 2026. Language --> Scientific publications require an abstract in English or German; full texts may be in any language. Translation and access limitations will be documented. 4. Information sources and search strategy The main bibliographic sources are PubMed, APA PsycINFO via Ovid, and Scopus. The sensitive primary search combines S1 (ketamine/esketamine/arketamine and KAP-related acronyms), S2 (unipolar depression and related terms), and S3 (cognition/neurocognition and specific domains): S1 AND S2 AND S3. An additional focused search includes S4 (psychotherapy and named modalities): S1 AND S2 AND S3 AND S4. The focused set supplements rather than replaces the main set. No document-type, language, human, adult/age, subject-area, open-access, full-text, or country filters were applied to the preparatory database search strings; eligibility restrictions, including the English- or German-language abstract requirement, will be applied during screening. Database-specific subject headings and fields are documented in Appendix A. Scopus TITLE-ABS was selected for the main search after project-specific validation, without implying general superiority over TITLE-ABS-KEY. 4.1 Preparatory search history (not prospective screening) These are database-level retrieval counts before cross-database deduplication, not numbers of included studies. They may change at the final update. Scopus TITLE-ABS retrieved all five prespecified known-item reference studies also retrieved by TITLE-ABS-KEY. A prior KEY-only triage prioritized 43 PCC-near records for manual checking, none of which met inclusion criteria; the entire KEY-only set was not manually screened. A complete screening of KEY-only records may be undertaken as an additional sensitivity check; this remains optional and has not been performed. Any decision to undertake it, together with its timing and procedure, will be documented. Table: Database --> Main S1–S3 Focused S1–S4 Recorded search date PubMed --> 592 76 4 September 2026 APA PsycINFO (Ovid) --> 658 83 4 September 2026 Scopus TITLE-ABS --> 1,189 149 4 September 2026 4.2 Supplementary sources and citation tracking ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP), and Google Scholar will supplement the bibliographic searches, alongside backward reference checking and forward citation tracking of included studies and relevant reviews. All identified records will be evaluated using the prespecified eligibility criteria. Registered studies without publicly available results will be documented separately to characterize ongoing research and potential evidence gaps; they will not contribute to the descriptive synthesis of neurocognitive findings. Registry records containing sufficiently detailed public results may contribute to evidence mapping and descriptive synthesis when eligibility criteria are met. Findings available only through registries will be clearly distinguished from peer-reviewed publications. Registry entries and publications describing the same study will be linked to prevent double counting. Supplementary registry searches are planned using combinations of ketamine/esketamine, depression, psychotherapy, and cognitive-outcome terms. Search dates, interfaces, executed queries, and record counts will be logged. Targeted Google Scholar queries will be documented with the sorting method and the number of results screened; an operational stopping rule of screening up to the first 200 results per query, or all results when fewer are available, is planned. Forward citation tracking will use an identified citation index or publisher citation links, with the service and coverage recorded. Final query wording and operational details will be specified before these supplementary searches are undertaken. 4.3 Search updates and reproducibility The six database-specific strategies and their retrieval counts reported here are completed preparatory searches as of 4 September 2026, not the definitive searches for the review. Final database searches and an update before completion of screening or synthesis remain to be conducted. Their exact execution dates, strings, field restrictions, exports, record counts, and any changes relative to the preparatory searches will be documented. Appendix A preserves the six preparatory search strategies. 5. Record man
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7237125247
Cites:
Cited by:
Related to: